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Background: Prions, infectious agents associated with transmissible spongiform encephalopathy, are primarily
composed of the misfolded and pathogenic form (PrPSc) of the host-encoded prion protein. Because PrPSc retains
infectivity after undergoing routine sterilizing processes, the cause of bovine spongiform encephalopathy (BSE)
outbreaks are suspected to be feeding cattle meat and bone meals (MBMs) contaminated with the prion. To assess
the validity of prion inactivation by heat treatment in yellow grease, which is produced in the industrial
manufacturing process of MBMs, we pooled, homogenized, and heat treated the spinal cords of BSE-infected cows
under various experimental conditions.
Results: Prion inactivation was analyzed quantitatively in terms of the infectivity and PrPSc of the treated samples.
Following treatment at 140°C for 1 h, infectivity was reduced to 1/35 of that of the untreated samples. Treatment at
180°C for 3 h was required to reduce infectivity. However, PrPSc was detected in all heat-treated samples by using
the protein misfolding cyclic amplification (PMCA) technique, which amplifies PrPSc in vitro. Quantitative analysis of
the inactivation efficiency of BSE PrPSc was possible with the introduction of the PMCA50, which is the dilution ratio
of 10% homogenate needed to yield 50% positivity for PrPSc in amplified samples.
Conclusions: Log PMCA50 exhibited a strong linear correlation with the transmission rate in the bioassay; infectivity
was no longer detected when the log PMCA50 of the inoculated sample was reduced to 1.75. The quantitative
PMCA assay may be useful for safety evaluation for recycling and effective utilization of MBMs as an organic
resource.
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Transmissible spongiform encephalopathies (TSEs), in-
cluding scrapie in sheep and goats, chronic wasting disease
(CWD) in deer and elk, bovine spongiform encephalopathy
(BSE) in cattle, and Creutzfeldt–Jakob disease (CJD) in
humans, are infectious and fatal neurodegenerative dis-
eases [1]. Proteinaceous infectious agents called prions are
thought to be responsible for TSEs, which are character-
ized by the accumulation of the pathogenic form of prion
protein (PrPSc) in the nervous tissues of infected subjects
[2,3]. PrPSc is a conformational isoform of the normal
cellular prion protein (PrPC), which is rich in beta-sheet
structures, insoluble in mild detergents, and resistant to
protease digestion [4,5].
Because prions retain infectivity after undergoing rou-
tine sterilization processes [6], contaminated meat and
bone meals (MBMs) are suspected to be the source of
BSE infection [7,8]. MBMs are manufactured through a
multi-step process involving the crushing of carcasses in
a pre-breaker, heating at 120°C–140°C in yellow grease
(lower-quality grades of tallow) in a cooker, and degreas-
ing from solid material by an oil separator. To determine
BSE prion inactivation during the manufacturing process
of MBMs, industrial processes were replicated on a pilot
scale by using BSE-infected brains, and the infectivity of
processed materials in each step was investigated in de-
tail [9]. However, in reality, processing conditions for
MBMs differ among rendering houses producing com-
mercial MBMs. Since the efficiency of prion inactivation
could be influenced by various factors such as treatment
temperature, time, steam pressure in the cooker, size,
water and fat contents of carcasses [10-13], it is difficult
to identify the risks attributable to specific processing
conditions. Furthermore, PrPSc retained in the manufac-
turing process of MBMs remains to be elucidated.
The governments of many countries prohibited the
feeding of bovine MBMs following the feeding ban on
MBMs in the United Kingdom. A prion detection
method with high sensitivity and high accuracy must be
developed so that MBMs can be used safely in the
future. In addition, BSE prion is more resistant to phys-
ical and chemical treatments than are scrapie and CJD
prions [14]. Therefore, experiments using BSE-infected
materials are essential for the assessment of BSE prion
inactivation as they can be considered a worst case among
prions. In recent years, it has become possible to perform
in vitro amplification of PrPSc derived from various ani-
mals [15-21] by using protein misfolding cyclic amplifica-
tion (PMCA) [22]. We developed an ultrasensitive method
for BSE PrPSc detection using potassium dextran sulfate
(DSP) [20]. The PMCA technique can also be used to
quantitatively assess scrapie PrPSc [23-25], and our PMCA
method can be applied as an effective test for the assess-
ment of prion inactivation by monitoring residual BSEPrPSc [26]. In the present study, we investigated efficiency
of BSE prion inactivation following heat treatment in yel-
low grease by bioassay and quantitative PMCA.
Results
Infectivity of heat-treated homogenates
Long-term follow-up confirmed infectivity in the mice
intracerebrally inoculated with up to a 10–5 dilution of
the 10% homogenate of the pooled spinal cords (Table 1).
PrPSc accumulation was confirmed in the brains of the
diseased mice by western blotting and histopathological
analysis (data not shown). The infectious titer of the
homogenate was estimated to be 106.7 LD50 per gram. A
strong linear correlation (r = 0.99) between the incuba-
tion times and dilution ratios of the inoculated hom-
ogenate was observed in mice inoculated with up to a
10–3 dilution. Some mice inoculated with 10–4 and 10–5
diluted samples developed the disease after similar
prolonged survival times (735 or 736 days). In the ex-
treme dilution range, lower rate of transmission and
prolonged incubation time are generally observed in the
mice intracerebrally inoculated with prion-infected brain
homogenates. Since PrPSc tends to aggregate, these phe-
nomena may be due to the near-absence of PrPSc which
would have been almost completely diluted out.
Table 2 shows the effect of various heat treatments in
yellow grease on the BSE-infected spinal cord homoge-
nates. All mice inoculated with samples treated at 140°C
for 1 h died after an average of 304 days. The infectivity
was reduced to approximately 1/35 (log reduction = 1.54)
following the heat treatment. When the samples subjected
to temperatures above 140°C were used, 100% (180°C for
1 h) and 67% (160°C for 1 h) of the mice developed the
disease after prolonged average survival times. Regarding
the treatments for 3 h, infectivity was still detected in
some mice inoculated with the samples treated at 140°C
or 160°C. Because the incubation times of these diseased
mice were beyond the range of application of the regres-
sion line obtained using the titrated BSE-infected homoge-
nates, the log reduction of infectivity in each sample was
estimated to be more than 3.0. Meanwhile, mice inocu-
lated with samples treated at 180°C for 3 h did not exhibit
disease onset 790 days after inoculation.
PrPSc detection by PMCA
Figure 1a illustrates the results of the amplification
of the samples subjected to the grease-heating method.
No PrPSc signals were detected in the heat-treated sam-
ples by western blotting before amplification (data not
shown). After one round of amplification, PrPSc signals
were detected in the samples treated at 140°C–180°C for
1 h and at 140°C for 3 h. PrPSc signals were also detected
in both duplicate samples treated at 160°C and 180°C for
3 h after two or three rounds of amplification. In the
Table 1 Mean incubation time of TgBoPrP mice following
intracerebral inoculation of titrated bovine spongiform






time ± SD (days)
100 100% (7/7) 242 ± 14
10–1 100% (7/7) 279 ± 12
10–2 100% (5/5) 322 ± 42
10–3 100% (6/6) 367 ± 53
10–4 33% (2/6) 736, 736, >790
10–5 17% (1/6) 735, >790
10–6 0% (0/6) >790
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remained after the treatment, although infectivity was
not detected in the bioassay.
Quantitative analysis of PrPSc
Figure 1b shows the results of the amplification of each di-
luted sample of untreated BSE-infected spinal cord hom-
ogenate. PrPSc present in 10–7 dilution of the infected
homogenate was detected in all tubes after three rounds
of amplification. PrPSc signals were detected in three of
the 10–8 and one of the 10–9 dilutions after three rounds
of amplification. However, no additional tubes became
positive for PrPSc in these dilutions after four rounds of
amplification. No signals were detected in the more ex-
treme dilution ranges even after four rounds of amplifica-
tion. Thus, the PMCA50 of the 10% homogenate was
calculated to be 108.5 units on the basis of the results
obtained from the fourth round of amplification.
To evaluate the PrPSc inactivation efficiency of each heat
treatment, we estimated the PMCA50 from the results
obtained at the fourth round of amplification of serial 10-
fold dilutions of heat-treated samples. Serial PMCA was
sufficiently sensitive to detect PrPSc in these diluted sam-
ples (Figure 2). The log reduction of PMCA50 values of
the heat-treated samples are shown in Table 2. Regarding
the treatments for 1 h, PrPSc inactivation appeared to be
most efficient in the samples treated at 160°C. This findingTable 2 Effects of various heat treatments in yellow grease o
Temperature Time (h) Transmission rate
(diseased/total)
140°C 1 100% (6/6)
3 83% (5/6)
160°C 1 67% (4/6)
3 17% (1/6)
180°C 1 100% (6/6)
3 0% (0/6)
*,†,‡ Significant differences (*: p < 0.01; †, ‡: p < 0.05) were observed among mice wi
superscript character.is concordant with the observations of partial transmission
of infectivity (67%) in the mice inoculated with this sample
and prolonged incubation times of the diseased mice. Log
PMCA50 decreased with extended heat treatment time:
although 180°C for 3 h was the most effective treatment, it
was unable to completely inactivate the proportion of
PrPSc that is amplifiable by serial PMCA.
Figure 3 shows the relationships between the transmis-
sion rate in the bioassay and the log PMCA50 values of
the inoculated samples. A strong linear correlation (r =
0.97) was observed between the log PMCA50 values and
transmission rate. When the log PMCA50 exceeded 5.25,
the transmission rate in the bioassay reached 100% as
observed in the mice inoculated with samples treated at
140°C or 180°h for 1 h. Infectivity was not detected in
the mice when the log PMCA50 of the inoculated sample
was reduced to 1.75.
Discussion
In this study, BSE prion inactivation was analyzed quan-
titatively in terms of infectivity and the PrPSc contents of
the samples after heat treatment in yellow grease.
Following treatment at 140°C for 1 h, which is the heat
treatment condition generally used for carcasses in ren-
dering houses in Japan, the infectivity of the BSE-
infected spinal cord homogenate was reduced to at most
1/35 of that of the untreated control samples; further-
more, PrPSc retained its capability for in vitro propagation.
Because carcasses are usually heat treated in closed
cookers, prions are affected by the steam pressure from
the water contained in the carcass. If a sufficient amount
of water is present in the carcass, prion inactivation may
proceed more efficiently in the cooker than under atmos-
pheric pressure. However, some degree of BSE infectivity
was still detected after autoclaving at 133°C in spiked raw
materials with high infectivity levels [26]. Furthermore,
the precise effects of high-pressure steam on carcasses
submerged in yellow grease are not known. Therefore,
high-risk materials such as brains and spinal cord should
be excluded from the rendering process for effective in-
activation of BSE prion.n BSE-infected spinal cord homogenates
Mean incubation





304 ± 13*,‡ 1.54 2.75
382 ± 64, >790 >3.0 4.0
471 ± 80*,†, >790 >3.0 3.5
514, >790 >3.0 6.0
380 ± 25†,‡ >3.0 3.25
>790 >3.0 6.75
th respect to the mean incubation times as indicated by identical
Figure 1 Detection of bovine spongiform encephalopathy (BSE) PrPSc by serial potassium dextran sulfate-protein misfolding cyclic
amplification. (A) Homogenates (10%) of BSE-infected spinal cords treated in yellow grease at 140°C–180°C for 1 or 3 h were diluted 10–1 with
the PrPC substrate and amplified by serial PMCA. Duplicate samples were analyzed after each round (R1–R4) of amplification by western blotting
after digestion with proteinase K. The lanes labeled “N” are samples in which only the PrPC substrate was treated in the same manner. Horizontal
lines indicate the positions of molecular-weight markers corresponding to 37, 25, 20, and 15 kDa. (B) Homogenates (10%) of the heat-untreated
BSE-infected spinal cords were diluted 10–7 to 10–10 with the PrPC substrate and amplified in four tubes by serial PMCA.
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after heat treatment of scrapie-infected hamster brains
under various experimental conditions [27]. The PMCA
results were concordant with bioassay results. However,
BSE PrPSc was detected in the samples treated at 180°C
for 3 h, although infectivity was not detected in the bio-
assay. There are several possible explanations for this dis-
crepancy between infectivity and PrPSc occurrence. For
example, BSE PrPSc might contain various forms of PrPSc
with different amplification properties and infectivity, and
a PMCA-compatible form of PrPSc with low or noFigure 2 Quantitative analysis of bovine spongiform encephalopathy
BSE-infected spinal cords treated in yellow grease at 140–180°C for 1 or 3 h
sulfate-protein misfolding cyclic amplification. The dilution ratios examined
after each round (R1–R4) of amplification by western blotting after digestio
the PrPC substrate was treated in the same manner. Horizontal lines indicat
20, and 15 kDa.infectivity might predominate after heat treatment and be
maintained over other forms throughout the amplification
process. However, in the present study, the log PMCA50
values were strongly correlated with the transmission rate
in the bioassay (Figure 3), suggesting that such PMCA-
compatible but less-infectious PrPSc was not selectively
amplified in vitro.
In our previous paper, we demonstrated our amplifica-
tion system was highly sensitive and accurate, and no
spontaneous generation of PrPSc was observed in the
amplification of various kind of samples derived from(BSE) PrPSc in heat-treated samples. Homogenates (10%) of
were diluted with the PrPC substrate and amplified by serial dextran
in each sample are indicated. Quadruplicate samples were analyzed
n with proteinase K. The lanes labeled “N” are samples in which only
e the positions of molecular-weight markers corresponding to 37, 25,
Figure 3 Relationship between the log PMCA50 and
transmission rate in the bioassay. A strong linear relationship
(r = 0.97) was observed in the samples treated at 140°C–180°C for
1 h (●) and 3 h (▲).
Figure 4 Detection of PrPSc in brains of asymptomatic mice. A
10% brain homogenate from five (#1-#5) of six asymptomatic mice
inoculated with 10–6 dilution of infected homogenate (Table 1) was
prepared, and amplified by serial PMCA. Quadruplicate samples were
analyzed after each round (R1–R4) of amplification by western
blotting after digestion with proteinase K. One (#1 and #3), two (#5)
and four (#2) of the quadruplicate samples were found to be
positive for PrPSc after three or four rounds of amplification. No PrPSc
signal was detected in #4 mouse. The eight lanes labeled “N” are
samples in which only the PrPC substrate was treated in the same
manner. Horizontal lines indicate the positions of molecular-weight
markers corresponding to 37, 25, 20, and 15 kDa. nt: not tested.
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based on quadruplicate amplification was also done in
our previous study [26], and we confirmed that similar
PMCA50 values (around 10
11 per gram) were obtained in
two independent studies. In the present study, the
PMCA50 of the BSE-infected spinal cords was estimated
to be 1011.6 per gram, which is approximately 80,000-
fold greater than the corresponding intracerebral LD50
per gram (106.7) determined by the bioassay. The
PMCA50/LD50 per gram of BSE prion was considerably
higher than those of scrapie prion strains (160–4000
fold) [25]. If this ratio reflects the number of PrPSc parti-
cles that compose an infectious unit of prions, more
PrPSc particles might participate in an infectious unit of
BSE prions; moreover, such a large mass of PrPSc parti-
cles might be processed into several smaller ones with
lower infectivity in vivo.
Alternatively, PrPSc accumulation might proceed in
animals inoculated with PrPSc when the PrPSc concen-
tration is below a specific cut-off, but the animals might
not develop the disease within their lifetimes. Actually,
clinically asymptomatic infections are known as the sub-
clinical infection stage [28-30]. In the present study,
we examined PrPSc in brains of asymptomatic mice inoc-
ulated with titrated BSE-infected homogenate, and PrPSc
was found at various levels in four of five mice ino-
culated with 10–6 dilution of the infected homogenate
(Figure 4). Therefore, pathogenicity might be detected
by serial transmission in animals as in the case of serial
PMCA. If so, the detection sensitivity of the bioassay
used in the present study may not be sufficiently high
for proper safety evaluation, because ecycling of BSE-
infected bovine tissues possibly augments the concen-
tration of PrPSc in commercial MBMs if the carcasses
contain infinitesimal amounts of prion.Another aspect of heat treatment in yellow grease is
that higher-temperature treatments do not necessarily
inactivate BSE prion more effectively. In the case of heat
treatment for 1 h, the results of both the bioassay and
PMCA indicate that BSE prion inactivation proceeded
more effectively with treatment at 160°C rather than
at 180°C. Samples treated at 180°C were dark brown,
suggesting that the surface was scorched during treat-
ment. In such high-temperature conditions, thermal
conduction may be inhibited by scorching of the sample
periphery, consequently requiring longer treatment time
to reach thermal equilibrium in the sample. Extension of
the treatment time to 3 h was actually necessary for the
loss of infectivity. However, further studies are needed to
confirm the above possibility.
Conclusions
In this study, we demonstrated that heat treatment at
180°C for 3 h is required for the loss of infectivity of BSE
prion in grease heating in our experimental conditions.
Furthermore, BSE PrPSc retains amplification ability even
after such a treatment. The inactivation efficiency of BSE
PrPSc could be quantitatively analyzed with the introduc-
tion of the PMCA50, which is strongly correlated with the
transmission rate in the bioassay. The serial PMCA tech-
nique is more practical and less time consuming than bio-
assays, and may be applicable for monitoring residual
Yoshioka et al. BMC Veterinary Research 2013, 9:134 Page 6 of 8
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and useful for safety evaluation for recycling and effective
utilization of MBMs as an organic resource.
Methods
Experimental heat treatment procedure
All animal experiments were approved by the Animal
Care and Use Committee of the National Institute of
Animal Health (approval IDs: 450 and 08-008) in ac-
cordance with the Guidelines for Animal Transmissible
Spongiform Encephalopathy Experiments of the Ministry
of Agriculture, Forestry, and Fisheries of Japan. Spinal
cords were obtained from four cows experimentally in-
oculated with BSE at the terminal stage of the disease.
The infected materials were pooled and homogenized
using a blender. Pure homogenate (0.5 g) was placed on
a strip of aluminum foil (2 cm × 2 cm) and stored at –
80°C until further use. For use, the homogenate with the
aluminum foil was thawed at room temperature and
then immersed in 15 mL yellow grease preheated to
140°C, 160°C, or 180°C in a ceramic crucible by using an
electric heating device (ND-M11, Nissin Rika, Tokyo,
Japan). The yellow grease used was obtained from a ren-
dering house in Japan. The crucible was covered, and a
thermosensor was inserted through a hole in the cover
to monitor the temperature of the yellow grease. The
yellow grease was, then, kept for 1 or 3 h at the desired
temperature. The homogenate sample firmly adhered to
the surface of aluminum foil and was not broken into
pieces during the heat treatment. After the treatment,
the homogenate with the aluminum foil was removed
from the yellow grease with tweezers and placed on a
paper towel for absorption of the excess yellow grease.
The weights of the homogenates were reduced to 60–
70% of their original weights. The resultant materials
were thoroughly crushed with a mortar, and suspended
in PBS at 10% (w/v). Insoluble materials were separated
by brief centrifugation, and aqueous fraction was stored
at –80°C until further use.
Bioassay
Infectivity titer using transgenic mice overexpressing bo-
vine PrPC is generally 100-1000 times higher than that
using cows. Therefore, more accurate estimation of BSE
infectivity is able to be conducted by using such mice.
The heat-treated samples were injected intracerebrally
into six Tg(BoPrP)4092HOZ/Prnp0/0 (TgBoPrP) trans-
genic mice (20 μL per mouse) overexpressing bovine
PrPC [31]. To determine the infectivity titer, serial 10-
fold dilutions of the 10% homogenate of the untreated
spinal cords were prepared in PBS and injected intrace-
rebrally into five to seven TgBoPrP mice (20 μL per
mouse). After inoculation, the mice were evaluated daily
for signs of infection. The lethal dose (LD50) wasdetermined according to the 50% endpoint calculation
method. Mean incubation times of the diseased mice
were analyzed by one-way ANOVA and Tukey’s multiple
comparison test.
PMCA
Bovine PrPSc was amplified as described previously [20].
Briefly, the brains of TgBoPrP transgenic mice and PrP
knockout (PrP0/0) mice were homogenized separately in
PBS containing 1% Triton X-100 and 4 m mol L–1
EDTA. After centrifugation at 4500 × g for 5 min, the
supernatants were mixed in PrP0/0/TgBoPrP (5:1). A
mixture containing 0.5% DSP was used as the PrPC sub-
strate for PMCA.
The 10% homogenates of heat-treated samples were
mixed at 1:9 with the PrPC substrate (total volume,
100 μL) in electron beam-irradiated polystyrene tubes.
Amplification was performed in duplicate with a fully
automatic cross-ultrasonic protein-activating apparatus
(Elestein 070-CPR, Elekon Science, Chiba, Japan), which
has a capacity to generate high ultrasonic power (700 W).
PMCA amplification was performed by 40 cycles of sonic-
ation (3-s pulse oscillations repeated 5 times at 1-s inter-
vals), followed by incubation at 37°C for 1 h with agitation.
For serial PMCA, 1:5 dilution of the PMCA product and
subsequent amplification was repeated twice.
To evaluate the inactivation efficiency of BSE PrPSc by
heat treatment, the PMCA50, which is the dilution ratio of
the 10% homogenate needed to yield 50% PrPSc positivity
for amplified samples, was determined. Serial 10-fold dilu-
tions of the 10% homogenate of the heat-treated and un-
treated samples were prepared and mixed 1:9 with the
PrPC substrate (total volume, 80 μL) and amplified in elec-
tron beam-irradiated eight-strip polystyrene tubes (076-
96, Elekon Science). Amplification was performed in
quadruplicate using 40 cycles of sonication (pulse oscilla-
tion for 5 s, repeated 5 times at 1-s intervals), followed by
incubation at 37°C for 1 h with agitation. For serial
PMCA, 1:5 dilution of the amplified product and subse-
quent amplification was repeated 3 times. The PMCA50
was estimated from the results of the fourth round of
amplification by using the 50% endpoint calculation
method.
Western blotting
The amplified samples (10 μL) were mixed with 10 μL
proteinase K solution (100 μg mL–1) and incubated at
37°C for 1 h. The digested samples were mixed with
20 μL 2× SDS sample buffer and incubated at 100°C for
5 min. The samples were separated by SDS-PAGE and
transferred onto a polyvinylidene fluoride membrane
(Millipore, Bedford, MA). After the membrane was
blocked, it was incubated for 30 min with a horseradish
peroxidase (HRP)-conjugated T2 monoclonal antibody
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oped using the Luminata Forte Western HRP Substrate
(Millipore) according to the manufacturer’s instructions.
Chemiluminescence signals were analyzed with a Light
Capture System (Atto, Tokyo Japan).
Histopathological analysis
The left hemispheres of the brains were fixed in 10% buff-
ered formalin for neuropathological analysis. Coronal
brain sections were immersed in 98% formic acid to re-
duce infectivity and embedded in paraffin wax. Sections
(4 μm thick) were cut and stained with hematoxylin and
eosin, and analyzed immunehistochemically as described
previously [20].
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